Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Gene Expression Profile Prediction under Drug Action Based on Generative Adversarial Networks.

Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform

Learning the Cellular Activity Representation Based on Gene Regulatory Networks for Prediction of Tumor Response to Drugs

Conditional generative adversarial network for gene expression inference

GANsDTA: Predicting Drug-Target Binding Affinity Using GANs.

GADRP: graph convolutional networks and autoencoders for cancer drug response prediction

scPreGAN, a deep generative model for predicting the response of single-cell expression to perturbation

Generative adversarial networks applied to gene expression analysis: An interdisciplinary perspective

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

drGAT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network

Deep learning assisted cancer disease prediction from gene expression data using WT-GAN

Deep generative neural network for accurate drug response imputation

High-content image generation for drug discovery using generative adversarial networks

Predicting Drug Responses by Propagating Interactions through Text-Enhanced Drug-Gene Networks

Graph Convolutional Autoencoder and Generative Adversarial Network-Based Method for Predicting Drug-Target Interactions

ctGAN: combined transformation of gene expression and survival data with generative adversarial network

Abstract 4397: Pathway-based Drug Combinatory Synergy Prediction Using Gene Expression and Essentiality Data

An Innovative Multi-Omics Model Integrating Latent Alignment and Attention Mechanism for Drug Response Prediction

Predicting LncRNA-Disease Association Based on Generative Adversarial Network

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery